FOOTHILL RANCH, Calif., Sept. 15, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it hosted nearly 400 dental professionals last Thursday evening during a panel discussion on the NEW Journal of Periodontology landmark study from the McGuire Institute comparing periodontal flap surgery to BIOLASE's REPAIR Perio laser protocol in managing periodontitis.
Members of the investigating team, Dr. Rick Heard and Dr. Donald Clem, along with a panel of Periodontists reviewed the study's design, protocol development, study findings including superior patient related outcomes, and the clinical implications moving forward for dental practices.
The learning objectives of the webinar were to:
- Understand the American Academy of Periodontology's Best Evidence Consensus recommendations for studies and how this study meets them
- Learn the advantages of minimally invasive REPAIR Perio laser protocol for patient reported outcomes, compared to periodontal flap surgery, and
- Determine how all tissue laser technology can enhance today's periodontal practice
Superior patient related outcomes and periondist findings included:
- Patients experienced less bruising, swelling and pain with the REPAIR Perio laser treatment compared to MIST
- Periodontists that were involved in the study reported faster procedure times compared to periodontal flap surgery
"We are excited that we were able to bring together so many dental professionals to discuss the landmark study performed by The McGuire Insititute and the superior patient reported outcomes of Waterlase-assisted treatment of periodontitis," commented Todd Norbe, President and Chief Executive Officer of BIOLASE. "The recently published results of the study and the benefits of our REPAIR Perio laser protocol have generated significant enthusuiasm within the periodontal community and we look forward to doing more events like this in the future."
About BIOLASE, Inc.
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 261 patented and 52 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/biolase-hosts-nearly-400-dental-professionals-during-webinar-on-landmark-study-on-lasers-and-managing-periodontitis-301130932.html
SOURCE BIOLASE, Inc.